Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Business Wire
In the Phase 3 CheckMate -227 trial, the one-year progression-free survival rate was more than triple with the combination versus chemotherapy (43% vs. 13%) in first-line non-small cell lung cancer patients with high TMB =10 mut/Mb Near doubling of overall response rate with the combination (45.3%) versus chemotherapy (26.9%); 68% of responders had ongoing responses at one year (25% with chemotherapy) Grade 3-4 treatment-related adverse event rate with the Opdivo plus low-dose Yervoy combination was 31% versus 36% with chemotherapy PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced initial results from the pivotal Phase 3 study, CheckMate -227, evaluating the Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab, 1 mg/kg) combination in first-line advanced non-small cell lung cancer (NSCLC) patients with high tumor mutational burden
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off [Seeking Alpha]Seeking Alpha
- Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat [Yahoo! Finance]Yahoo! Finance
- Why Bristol Myers Squibb Stock Is Sinking Today [Yahoo! Finance]Yahoo! Finance
- Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/22/24 - Form DEFA14A
- BMY's page on the SEC website